FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Regeneron Reaches Drug Pricing Deal, Gains US Nod for Rare Deafness Therapy

By

Regeneron Pharmaceuticals (REGN) has struck an agreement with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported on Thursday, citing a person familiar with the matter.

Regeneron was the last company asked by Trump to align US costs with those in other developed countries under a most favored nations policy.

The administration has pressured major pharmaceutical firms to sign pricing agreements to offer discounted prices or align costs with international markets, in exchange for incentives such as tariff exemptions.

According to the report, the Food and Drug Administration is expected to authorize the treatment for an ultra-rare inherited hearing-loss condition caused by a genetic mutation.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $763.89, Change: $+17.31, Percent Change: +2.32%

Related Articles

Wire

New Hope Completes AU$300 Million Convertible Notes Offering

New Hope (ASX:NHC) completed a AU$300 million issuance of 2.625% senior unsecured convertible notes due 2032 and the concurrent repurchase of AU$293.3 million of its existing 2029 convertible notes, according to a Thursday filing with the Australian bourse.The new notes are expected to be listed on the Singapore Exchange Securities Trading on or around Thursday, per the filing.The repurchased 2029 notes, which account for around 98% of the outstanding notes, will be cancelled under their terms, the filing said. The company also plans to redeem the remaining AU$6.7 million of notes at par plus accrued interest prior to maturity.

ASX:NHC
Wire

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

Telix Pharmaceuticals (ASX:TLX) said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is "substantially complete."After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.

ASX:TLX
Wire

Century Communities Q1 Adjusted Earnings, Revenue Fall

Century Communities (CCS) reported Q1 adjusted earnings late Wednesday of $0.88 per diluted share, down from $1.39 a year earlier.Three analysts polled by FactSet expected $0.59.Revenue for the three months ended March 31 fell to $789.7 million from $903.2 million a year earlier.Four analysts surveyed by FactSet expected $807.7 million.

$CCS